Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort studyChristopher M. Clark, Daniel Skovronsky, Marwan N. Sabbagh et al.|The Lancet Neurology|2012Cited by 846
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive declineP. Murali Doraiswamy, Reisa A. Sperling, Robert E. Coleman et al.|Neurology|2012Cited by 228
Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer diseaseAdam Fleisher, Eric M. Reiman, Kewei Chen et al.|Neurobiology of Aging|2012Cited by 210
Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter studyMichael J. Pontecorvo, P. Murali Doraiswamy, Reisa A. Sperling et al.|Molecular Psychiatry|2014Cited by 196
Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individualsReisa A. Sperling, Michael J. Pontecorvo, Keith A. Johnson et al.|Neurobiology of Aging|2012Cited by 127